211 related articles for article (PubMed ID: 28794454)
1. Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide.
Jeanne A; Untereiner V; Perreau C; Proult I; Gobinet C; Boulagnon-Rombi C; Terryn C; Martiny L; Brézillon S; Dedieu S
Sci Rep; 2017 Aug; 7(1):7700. PubMed ID: 28794454
[TBL] [Abstract][Full Text] [Related]
2. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma.
Jeanne A; Martiny L; Dedieu S
Pediatr Res; 2017 Mar; 81(3):480-488. PubMed ID: 27842053
[TBL] [Abstract][Full Text] [Related]
4. The small leucine-rich proteoglycan lumican inhibits melanoma progression.
Vuillermoz B; Khoruzhenko A; D'Onofrio MF; Ramont L; Venteo L; Perreau C; Antonicelli F; Maquart FX; Wegrowski Y
Exp Cell Res; 2004 Jun; 296(2):294-306. PubMed ID: 15149859
[TBL] [Abstract][Full Text] [Related]
5. Lumican-null mice are susceptible to aging and isoproterenol-induced myocardial fibrosis.
Chen SW; Tung YC; Jung SM; Chu Y; Lin PJ; Kao WW; Chu PH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1304-1311. PubMed ID: 27939890
[TBL] [Abstract][Full Text] [Related]
6. Lumican Inhibits In Vivo Melanoma Metastasis by Altering Matrix-Effectors and Invadopodia Markers.
Karamanou K; Franchi M; Proult I; Rivet R; Vynios D; Brézillon S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917849
[TBL] [Abstract][Full Text] [Related]
7. Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes.
Brézillon S; Radwanska A; Zeltz C; Malkowski A; Ploton D; Bobichon H; Perreau C; Malicka-Blaszkiewicz M; Maquart FX; Wegrowski Y
Cancer Lett; 2009 Sep; 283(1):92-100. PubMed ID: 19394140
[TBL] [Abstract][Full Text] [Related]
8. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
9. Collagen fibril assembly during postnatal development and dysfunctional regulation in the lumican-deficient murine cornea.
Chakravarti S; Zhang G; Chervoneva I; Roberts L; Birk DE
Dev Dyn; 2006 Sep; 235(9):2493-506. PubMed ID: 16786597
[TBL] [Abstract][Full Text] [Related]
10. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma.
Brézillon S; Venteo L; Ramont L; D'Onofrio MF; Perreau C; Pluot M; Maquart FX; Wegrowski Y
Clin Exp Dermatol; 2007 Jul; 32(4):405-16. PubMed ID: 17490399
[TBL] [Abstract][Full Text] [Related]
11. Lumican inhibits B16F1 melanoma cell lung metastasis.
Brezillon S; Zeltz C; Schneider L; Terryn C; Vuillermoz B; Ramont L; Perrau C; Pluot M; Diebold MD; Radwanska A; Malicka-Blaszkiewicz M; Maquart FX; Wegrowski Y
J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():15-22. PubMed ID: 20083847
[TBL] [Abstract][Full Text] [Related]
12. Role of Cys41 in the N-terminal domain of lumican in ex vivo collagen fibrillogenesis by cultured corneal stromal cells.
Carlson EC; Mamiya K; Liu CY; Gendron RL; Birk DE; Funderburgh JL; Kao WW
Biochem J; 2003 Feb; 369(Pt 3):461-8. PubMed ID: 12381269
[TBL] [Abstract][Full Text] [Related]
13. Lumican Peptides: Rational Design Targeting ALK5/TGFBRI.
Gesteira TF; Coulson-Thomas VJ; Yuan Y; Zhang J; Nader HB; Kao WW
Sci Rep; 2017 Feb; 7():42057. PubMed ID: 28181591
[TBL] [Abstract][Full Text] [Related]
14. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican.
D'Onofrio MF; Brézillon S; Baranek T; Perreau C; Roughley PJ; Maquart FX; Wegrowski Y
Biochem Biophys Res Commun; 2008 Jan; 365(2):266-72. PubMed ID: 17981144
[TBL] [Abstract][Full Text] [Related]
15. Development of myotendinous-like junctions that anchor cardiac valves requires fibromodulin and lumican.
Dupuis LE; Doucette L; Rice AK; Lancaster AE; Berger MG; Chakravarti S; Kern CB
Dev Dyn; 2016 Oct; 245(10):1029-42. PubMed ID: 27503167
[TBL] [Abstract][Full Text] [Related]
16. Functions of lumican and fibromodulin: lessons from knockout mice.
Chakravarti S
Glycoconj J; 2002; 19(4-5):287-93. PubMed ID: 12975607
[TBL] [Abstract][Full Text] [Related]
17. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response.
Nikitovic D; Papoutsidakis A; Karamanos NK; Tzanakakis GN
Matrix Biol; 2014 Apr; 35():206-14. PubMed ID: 24060754
[TBL] [Abstract][Full Text] [Related]
18. Loss of ADAM9 Leads to Modifications of the Extracellular Matrix Modulating Tumor Growth.
Abety AN; Pach E; Giebeler N; Fromme JE; Aramadhaka LR; Mauch C; Fox JW; Zigrino P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32906814
[TBL] [Abstract][Full Text] [Related]
19. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential.
Lončar-Brzak B; Klobučar M; Veliki-Dalić I; Sabol I; Kraljević Pavelić S; Krušlin B; Mravak-Stipetić M
Clin Oral Investig; 2018 Mar; 22(2):1071-1082. PubMed ID: 28779221
[TBL] [Abstract][Full Text] [Related]
20. Lumican, a small leucine-rich proteoglycan substituted with keratan sulfate chains is expressed and secreted by human melanoma cells and not normal melanocytes.
Sifaki M; Assouti M; Nikitovic D; Krasagakis K; Karamanos NK; Tzanakakis GN
IUBMB Life; 2006 Oct; 58(10):606-10. PubMed ID: 17050378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
